Domestic entecavir declared to build up the market and fought miserably

In terms of drug sales ranking of sample hospitals, entecavir ranked 27th in 2012, 15th in 2013, up 12 places, and has become the core product of nucleoside antiviral drugs China is a country with frequent liver diseases, which determines that China is a huge market of drugs for liver diseases In the late 1990s, many multinational companies, such as GlaxoSmithKline, Bristol Myers Squibb and Novartis, focused their attention on the Chinese market, and the imported hepatology drugs immediately entered the market and quickly occupied the leading position in the market In recent years, domestic enterprises have joined in this field, and the market competition is extremely fierce According to the statistics of the World Health Organization, about 2 billion people in the world are infected with hepatitis B virus, and more than 350 million people suffer from chronic (long-term) hepatitis B Among them, about 1 / 3 of the hepatitis B patients in China, and the total annual cost of hepatitis B treatment in China is more than 100 billion yuan Under the background that the coverage of the national medical security system has been greatly improved, the market of hepatitis B treatment drugs has grown in an all-round way At present, there are two main types of hepatitis B drugs in the global market: one is interferon, an immunomodulator, which mainly includes common interferon and polyglycosylated interferon, that is, long-acting interferon The other is nucleoside or nucleoside analogue At present, there are many nucleotide analogue products on the market in the world, including entecavir, tenofovir dipivoxil, lamivudine, adefovir and telbivudine According to the data of global best-selling drugs, in 2012, the global sales of entecavir reached US $1.526 billion, a year-on-year increase of 27.6%, maintaining a high growth rate From 2006 to 2012, its compound growth rate was 62.5% In the past six years, it has maintained a rapid growth The sales volume increased from 83 million dollars in 2006 to 1526 million dollars in 2012, an increase of nearly 18 times Entecavir is one of the most rapidly growing nucleoside antiviral drugs in recent years Several other products, such as tenofovir, lamivudine and adefovir, have gained steady growth According to the data of 22 sample hospitals in China, in 2013, the amount of drug use of four major anti hepatitis B drugs, entecavir, adefovir, lamivudine and telbivudine, was nearly 1.86 billion yuan, an increase of 16.2% year on year In 2013, the sales volume of entecavir was 920 million yuan, with a year-on-year growth of 31.1%, and the growth rate was high-profile Borudine accounts for 70% of the market in China The largest antiviral drug used is entecavir, which is mainly used for the treatment of hepatitis B Entecavir is the first nucleoside hepatitis B treatment drug listed in the United States by Squibb Company in 2005 Its trade name is bolutin, and it entered the Chinese market in 2006 According to the statistical data in recent years, entecavir has performed well in the domestic market, and its sales soon exceeded the two most classic old varieties, lamivudine and adefovir dipivoxil According to the data of 22 sample hospitals in China, in 2013, the sales volume of China US Shanghai Squibb was 646 million yuan, accounting for 70.1% of the total, an increase of 23.0% over the same period According to the sales trend from 2006 to 2013, the compound growth rate is 51.0% The sales volume increased from 36.15 million yuan in 2006 to 646 million yuan in 2013, an increase of nearly 18 times The sales volume of Runzhong of Jiangsu Zhengda Tianqing Pharmaceutical Co., Ltd was 214 million yuan, accounting for 23.2% of the market share, with a growth rate of 47.0% over the same period According to the sales trend from 2010 to 2013, the compound growth rate is 177.9% The sales volume increased from 9.97 million yuan in 2010 to 214 million yuan in 2013, an increase of nearly 21 times The sales volume of products of Jiangsu Suzhou Dongrui, Jiangxi Qingfeng pharmaceutical and Fujian guangshengtang Pharmaceutical Co., Ltd was 61.25 million yuan, accounting for only 6.7% of the total, with an increase rate of 96.0% over the same period The products of the above three enterprises are listed later and share is relatively small According to the data of the national drug review center, there are nine enterprises that have already batch produced entecavir, including common tablets, dispersible tablets and capsules In February 2010, entecavir dispersible tablet of Jiangsu Zhengda Tianqing Pharmaceutical Co., Ltd was listed under the trade name of "Runzhong", becoming the first enterprise approved to produce the preparation in China At present, there are more than 70 enterprises applying for entecavir in China In addition to the common tablets, capsules and dispersive tablets involved above, the new dosage forms applied for are: orally disintegrating tablets, granules, oral solutions, oral film dissolving agents, etc Entecavir is a popular heavy-duty product The declaration enterprises have a phenomenon of clustering There are more homogeneous products, and the market fighting is particularly fierce, or the drug price has dropped significantly The vision and pattern of the enterprise determine the present and future of the products Only by positioning the products and actively looking for the differences of the products in the market, can the enterprise be invincible in the rapidly changing market